Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alembic Pharmaceuticals Limited ( (IN:APLLTD) ) has issued an update.
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Diltiazem Hydrochloride Tablets USP in various dosages. This approval marks a significant milestone for Alembic, enhancing its portfolio of USFDA-approved products and strengthening its position in the global pharmaceutical market. The approval is expected to positively impact the company’s operations and market presence, offering stakeholders potential growth opportunities.
More about Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company, established in 1907 and headquartered in India. It is publicly listed and focuses on manufacturing and marketing generic pharmaceutical products globally. Alembic is recognized as a leader in branded generics in India, with its products being approved by regulatory authorities in many developed countries, including the USFDA.
Average Trading Volume: 11,217
Technical Sentiment Signal: Hold
Current Market Cap: 180.3B INR
Learn more about APLLTD stock on TipRanks’ Stock Analysis page.